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Abstract
Background: Very few data on anti-malarial efficacy are available from the Democratic Republic of Congo
(DRC). DRC changed its anti-malarial treatment policy to amodiaquine (AQ) and artesunate (AS) in 2005.
Methods: The results of two in vivo efficacy studies, which tested AQ and sulphadoxine-pyrimethamine
(SP) monotherapies and AS+SP and AS+AQ combinations in Boende (Equatorial province), and AS+SP,
AS+AQ and SP in Kabalo (Katanga province), between 2003 and 2004 are presented. The methodology
followed the WHO 2003 protocol for assessing the efficacy of anti-malarials in areas of high transmission.
Results: Out of 394 included patients in Boende, the failure rates on day 28 after PCR-genotyping
adjustment of AS+SP and AS+AQ were estimated as 24.6% [95% CI: 16.6–35.5] and 15.1% [95% CI: 8.6–
25.7], respectively. For the monotherapies, failure rates were 35.9% [95% CI: 27.0–46.7] for SP and 18.3%
[95% CI: 11.6–28.1] for AQ. Out of 207 patients enrolled in Kabalo, the failure rate on day 28 after PCR-
genotyping adjustment was 0 [1-sided 95% CI: 5.8] for AS+SP and AS+AQ [1-sided 95% CI: 6.2]. It was
19.6% [95% CI: 11.4–32.7] for SP monotherapy.
Conclusion: The finding of varying efficacy of the same combinations at two sites in one country highlights
one difficulty of implementing a uniform national treatment policy in a large country. The poor efficacy of
AS+AQ in Boende should alert the national programme to foci of resistance and emphasizes the need for
systems for the prospective monitoring of treatment efficacy at sentinel sites in the country.
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Background
The Democratic Republic of Congo (DRC) is a vast coun-
try covering more than two million square kilometres and
with an estimated population of 60 million people. In
2006, the malaria case fatality rate in children below five
years of age was 0.61 [1]. Very few evaluations of the effi-
cacy of artemisinin-based combinations have been con-
ducted in DRC. In 2004, one study presented day 28 PCR
genotyping-adjusted failure rates of 19.7% for artesu-
nate+sulphadoxine-pyrimethamine (AS+SP) and 6.7%
for AS+amodiaquine (AS+AQ) in South Kivu province [2].
Another study conducted in Rutshuru, a district near the
Rwandan border in Eastern DRC, reported day 14 PCR-
unadjusted cure rates of 63% and 24% for SP mono-
therapy and AS+SP, respectively [3].
The results of two in vivo efficacy studies conducted inde-
pendently in DRC in 2003–2004, when the National
Malaria Control Programme (NMCP) was in the process
of changing treatment policy to an artemisinin combina-
tion therapy (ACT) are presented. The NMCP introduced
AS+AQ as their first-line regimen in 2005 to replace SP
monotherapy for the treatment of uncomplicated
malaria. For one study, results on the molecular markers
of SP resistance are also presented. A good correlation has
been shown between mutations in the dihydrofolate reduct-
ase (dhfr) and dihydropteroate synthase (dhps) genes of Plas-
modium falciparum and resistance to pyrimethamine and
sulphadoxine, respectively [3-5].
Methods
Study site and population
The first study was located in Boende, Equatorial prov-
ince, in the northwest of the country and the second study
in Kabalo, Katanga province, in the southeast of DRC (Fig-
ure 1). Malaria is endemic in DRC with perennial trans-
mission in Boende and seasonal transmission in Kabalo,
with a peak between November and May. The ethics com-
mittee of the NMCP of the Democratic Republic of Congo
approved the two studies. The ethics review board of
Médecins Sans Frontières also reviewed the study protocol
for Kabalo. Written informed consent was obtained from
children's carers before enrolment.
Location of study sites Figure 1
Location of study sites.
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Study design and patients' follow-up
The two studies were open-label. The study methodology
was based on the WHO protocol for assessing efficacy of
anti-malarials in areas of high transmission [6]. In
Boende, SP and AQ monotherapies were evaluated as well
as in combination with artesunate (AS+AQ and AS+SP).
In Kabalo, SP monotherapy, AS+AQ and AS+SP were eval-
uated. There were slight methodological differences
between the two studies.
Eligibility criteria
In Boende, eligibility criteria were age between six and 59
months, axillary temperature ≥ 37.5°C, living in or within
5 km of Boende city and P. falciparum parasitaemia
between 2,000 and 200,000/μl. In Kabalo, due to the
unstable security situation and recruitment difficulties, it
was decided to extend the age group for inclusion to
between six months and 10 years and to accept P. falci-
parum parasitaemia between 1,000 and 200,000/μl. Only
children living less than half an hour's drive from the
study clinic in Kabalo city were enrolled. In both studies,
signs of severe malaria or any other serious health condi-
tion, intake of antimalarial treatment in the last seven
days and mixed malaria infection were exclusion criteria.
Sample size and randomization
Sample size was calculated using Epi Info 6 software (Cen-
tres For Disease Control, Atlanta, USA). For the study in
Boende, a sample size of 106 patients per arm was calcu-
lated using an estimated failure rate of 15%, a risk α of
5%, a precision of 7% and assuming 10% lost to follow-
up. In Kabalo, it was 60 patients per arm, using 15% fail-
ure rate, 5% risk α, 10% precision and 15% lost to follow-
up. In Boende, monotherapies and combination thera-
pies were evaluated sequentially because of the concern
that the study would be terminated early due to security
concerns. Therefore, children were initially randomly
allocated to SP or AQ, and then to AS+SP or AS+AQ, using
a ratio of 1:1 each time. In Kabalo, patients were allocated
randomly to AS+AQ, AS+SP or SP using a ratio of 1:1:1. In
both studies, randomization was in blocks of 12 and treat-
ment allocations were concealed in sealed opaque enve-
lopes, opened after consent was obtained.
Treatment
After randomization, haemoglobin, asexual parasitaemia
and presence of gametocytes were recorded at day 0, and
patients received the first dose of treatment: (i) SP (Fan-
sidar®, Roche, Basel, Switzerland) was given as a single
dose of approximately 1.25 mg/kg of pyrimethamine and
25 mg/kg of sulphadoxine; (ii) AQ (Camoquin®, Pfizer,
Dakar, Senegal) was given at a dose of 10 mg/kg/day once
daily for three days; and (iii) AS (Arsumax®, Sanofi Win-
throp AMO, Gentilly, France) was given at a dose of 4 mg/
kg once daily for three days. All doses were directly
observed at the health centre. Patients who vomited
within half an hour had the full dose replaced; if vomiting
occurred between 30 minutes and one hour after intake,
only half the dose was replaced. Study drugs manufac-
tured according to Good Manufacturing Practice stand-
ards were purchased for the purpose of the studies. A
capillary blood sample was also collected onto Whatman
grade 3 filter paper and stored on site for genotypic anal-
ysis if needed.
Participants' follow-up
Children were re-assessed clinically on days 1, 2, 3, 7, 14,
21, 28 and parasitologically on days 2, 3, 7, 14, 21 and 28
after the start of treatment. Participants were encouraged
to access the study clinic at any time between scheduled
visits in case of fever or any health problem. Indications
for withdrawal from the study were (i) vomiting any dose
of study drug twice (at which point intravenous quinine
was given), (ii) serious allergic reaction to the study drug,
(iii) other serious illness, (iv) intake of any drug with anti-
malarial properties during the period of follow-up, (v)
withdrawal of consent or (vi) failure to attend scheduled
visits. Treatment failures were treated with quinine hydro-
chloride. The WHO classification of treatment outcomes
was used with patients categorised as early treatment fail-
ures (ETF), late clinical failures (LCF), late parasitological
failures (LPF) on day 28 or adequate clinical and parasito-
logical response (ACPR) [6]. In the event of symptomatic
parasite recurrence (LCF) between days 10–28 of follow-
up or LPF, a second blood sample for polymerase chain
reaction (PCR) genotyping was collected (recurrences on
or before day 9 were assumed to be recrudescences). The
genotype of malaria parasites collected at day 0 and at the
time of parasitaemia recurrence was compared in order to
investigate if the recurrence resulted from recrudescence
or reinfection.
Laboratory procedures
In Boende, thick blood films were stained with Giemsa
10% for 10 to 20 minutes and with Giemsa 5% for 25
minutes in Kabalo. Parasite density was determined as the
number of parasites per 200 white blood cells (WBC),
assuming a total WBC count of 8,000/μl. If less than 10
parasites were read per 200 WBC, the count was extended
to 500 WBC. Microscopists reading the slides were blind
to the treatment allocation. In the two studies, there was
an independent double reading of all slides and resolu-
tion of discordant results (negative/positive/species or
parasitaemia discordance above 50%) by a third senior
reader. The third reading was taken as the final result. In
addition, an external quality control of 10% of slides
selected randomly from the screening, inclusion and fol-
low-up slides was performed. From the study in Boende,
slides were sent to the Institute of Tropical Medicine
(IMT), Antwerp (Belgium). Slides from Kabalo were sentMalaria Journal 2009, 8:192 http://www.malariajournal.com/content/8/1/192
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to the Amikuvu Regional Public Health Laboratory of
Goma and the National Institute of Biomedical Research
of Kinshasa (DRC). Haemoglobin was measured using
the Lovibond technique (Assistant Co., Sondheim Rhon,
Germany).
PCR genotyping to distinguish recrudescence from rein-
fection was performed in two different laboratories. For
Boende, the analysis was performed at the ITM of Ant-
werp, Belgium using merozoite surface protein-1 (msp1)
and merozoite surface protein-2 (msp2) P. falciparum gene
loci [7]. Infections were defined as recrudescent if at least
one common band for both markers was observed in the
presenting and recurrent infections. Recurrences were
defined as reinfection if completely different bands were
observed between the two infections in at least one of the
two markers. For the study in Kabalo, genotyping was per-
formed at the Epicentre laboratory at Mbarara University,
Uganda according to a published method using three P.
falciparum gene loci: msp1, msp2, and glutamate rich pro-
tein (glurp) [8]. The glurp  alleles were first compared
between baseline and post-treatment samples. If they
were different, the recurrence was attributed to a reinfec-
tion. If they were identical, then the msp1 and msp2 alleles
were compared between the 2 samples. If there was a com-
mon band on one or two msp markers, then the recurrence
was considered as recrudescence. If not, it was due to a
reinfection.
In Boende, additional blood samples were collected from
the children treated with SP as part of a multi-centre gen-
otyping study to look for molecular markers of antifolate
resistance. Analysis of mutations in codons 51, 59 and
108 of the dihydrofolate reductase (dhfr) and in codons
437 and 540 of the dihydropteroate synthase (dhps) genes
of P. falciparum was performed in the ITM of Antwerp, Bel-
gium using a real mutation-specific nested PCR and/or
restriction digestions [9,10]. The classification of samples
was based on a published methodology [11]. Each dhfr
and dhps codon was characterized as 'wild type' (no muta-
tion present), 'mixed' (both wild and mutant genotypes
clearly present in the same infection), or 'pure mutant'
(only mutant genotypes detected). The dhfr genotypes for
each infection were categorized as follows: 'wild type': no
mutation detected; 'single': infection involving parasites
with a single mutation; 'double': infection involving para-
sites with a double mutations and 'triple': infection
involving parasites with all three mutations detected. The
dhps genotypes were defined as wild type; single or double
mutations. Infections by parasites with a triple dhfr muta-
tion and double dhps mutation were categorized as 'quin-
tuple' mutation infections. These results have been
reported in detail elsewhere [12,13].
Analysis
Data were entered in Microsoft Excel® and analysed with
Stata® 10 (College Station, Texas, USA). Failure rates were
estimated using Kaplan-Meier survival analysis, in which
withdrawals, losses to follow-up and reinfections were
censored on the last day seen. Patients with missing or
indeterminate PCR results were censored on the closest
prior visit when the malaria smear result was negative.
Results
Boende study
A total of 1,005 children were screened between Septem-
ber 2003 and February 2004, of whom 394 (39.2%) were
enrolled (Figure 2). Three patients (0.8%) were lost to fol-
low up. Baseline characteristics are presented in Table 1.
Trends in fever, parasitaemia and haemoglobin over time
are presented in Table 2. More than one quarter of
patients treated with AS+SP or AS+AQ were parasitaemic
on day 7. Of 68 children still parasitaemic on day 7, 3 had
a fever and were classified as failures. The day 28 unad-
justed failure rates were 55.5% [95% confidence interval
CI: 46.0–65.4] for SP, 25.7% [95% CI: 18.3–35.4] for AQ,
52.2% [95% CI: 42.3–62.9] for AS+SP and 41.0% [95%
CI: 31.3–52.3] for AS+AQ. PCR genotyping results are
shown in Table 3. The end-point classifications after PCR
adjustment are shown in Table 4. For the monotherapies,
PCR adjusted failure rates were 35.9% [95% CI: 27.0–
46.7] for SP and 18.3% [95% CI: 11.6–28.1] for AQ. Fail-
ure rates on day 28 after PCR-genotyping adjustment of
AS+SP and AS+AQ were estimated as 24.6% [95%CI
16.6–35.5] and 15.1% [95%CI: 8.6–25.7], respectively.
There were 2 (2.6%) ETFs in the SP arm and none in the
other arms. Approximately half of all patients treated with
SP, AQ or AS+SP required re-treatment by day 28. No
child developed severe malaria after enrolment and there
were no deaths. Three children were withdrawn from the
study in the first week due to serious concomitant illness-
pneumonia, dysentery and suspected meningitis.
Out of a total of 179 slides sent for external quality con-
trol, 41 (22.9%) had positive-negative discordant results
during follow-up, 27 (65.7%) of them with very low par-
asitaemia (<100/μL). In three cases (1.7%), the discord-
ance affected classification of the patient's outcome:
patients with adequate therapeutic response were reclassi-
fied as ETF (two cases) and LPF (one case) based on the
results of the external quality control.
The results of the molecular markers of antifolate resist-
ance are presented in Table 5. There was 3/102, 2.9%
[95%CI: 0.6–8.3] quintuple dhps and dhfr mutation, one
with pure (1%) and two with mixed mutations, respec-
tively.Malaria Journal 2009, 8:192 http://www.malariajournal.com/content/8/1/192
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Kabalo study
A total of 880 children were screened between June and
December 2004, of whom 207 (23.5%) were enrolled
(Figure 2). During the study, investigators had to be evac-
uated from the site between October and December 2004
due to political instability. Twenty-seven patients
recruited during this time were excluded from the analysis
because of non-adherence to the study protocol. Baseline
characteristics were similar between the groups (Table 1).
Variations of fever, parasitaemia and haemoglobin over
time are presented in Table 2. About 10% of patients in
the AS+SP arm were parasitaemic on day 7. None had
Details of inclusions and follow-up in thestudies in Boende and Kabalo Figure 2
Details of inclusions and follow-up in thestudies in Boende and Kabalo.
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Table 1: Baseline characteristics of included patients in the studies in Boende and Kabalo
Boende Kabalo
Characteristics N SP
107
AQ
106
AS+SP
91
AS+AQ
90
SP
60
AS+SP
62
AS+AQ
58
Males, n (%) 56 (52.3) 54 (50.9) 45 (49.5) 46 (51.1) 26 (43.3) 37 (59.7) 36 (62.1)
Age months
median [range]
18
[6–59]
19
[6–59]
20
[6–56]
21
[6–56]
36
[8–96]
25
[7–108]
33.5
[7–108]
Weight kg
median [range]
9.2
[5.1–18]
10.3
[5.8–22]
9.7
[5.9–17]
9.9
[6.1–16.5]
11
[6–25]
11
[6.7–22]
11
[5.7–26]
MUAC mm
median [range]
140
[112–172]
142
[110–176]
142
[118–170]
138
[124–170]
146
[116–194]
148
[122–180]
149
[116–180]
Asexual parasitaemia (/
μl), GMR* [range]
26724
[2080–187200]
28992
[2097–189037]
26662
[2171–163840]
26134
[2073–186400]
22501
[1995–181970]
20352
[2455–162181]
19934
[2455–147911]
Temperature °C
median [range]
38.5
[37.5–40.2]
38.6
[37.5–40.5]
38.5
[37.5–40.6]
38.7
[37.5–40.6]
38.4
[37.5–40.5]
38.4
[37.5–41.0]
38.4
[37.5–40.5]
*GMR = geometric meanMalaria Journal 2009, 8:192 http://www.malariajournal.com/content/8/1/192
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fever. The day 28 unadjusted failure rates were 33.2%
[95% CI: 22.6–41.1] for SP, 16.6% [95% CI: 9.3–28.7] for
AS+SP and 8.8% [95% CI: 3.8–19.8] for AS+AQ. PCR gen-
otyping results are shown in Table 3. The final end-point
classifications after PCR adjustment are shown in Table 4.
The PCR adjusted failure rate for SP monotherapy on day
28 was 19.6% [95% CI: 11.4–32.7]. Corresponding fail-
ure rates were 0 [1-sided 95% CI: 5.8] for AS+SP and
AS+AQ [1-sided 95% CI: 6.2]. There were eight (16.7%)
ETFs in the SP monotherapy arm and none in the other
treatment arms.
No child developed severe malaria after enrolment and
there were no deaths. There was one serious adverse event
– a child diagnosed with acute severe malnutrition during
the first week. Of 182 slides sent for external quality con-
trol, 26 (14.3%) had positive-negative discordant results
during follow-up; none of them affected patients' out-
comes.
Discussion
These two independent studies document anti-malarial
efficacy in 2004 from locations in the east and west of
DRC, a country from which few such data have been
reported previously. Efficacy of SP was poor for both sites.
Efficacy of the AS-SP and AS-AQ combinations was poor
in Boende but high in Kabalo. The comparison between
the results of the two studies is limited by the difference in
study methodology. The age and parasitaemia enrolment
criteria were different and different genotypic methods
were used to discriminate recrudescence from reinfection.
Indeed, it is possible that the chance of being classified as
a recrudescence was higher in Boende where a two-loci
genotypic method was used compared to Kabalo, where a
three-loci method was used. The high failure rate of SP in
Boende is consistent with the molecular results for anti-
folate resistance, showing 61% had the triple dhfr muta-
tion, which is known to be associated with an increased
risk of treatment failure [3,4].
The threshold of resistance to SP at which it is no longer
useful to add artesunate is not well defined. In Kabalo, the
day 28-failure rate of SP was close to 20%, dropping to
zero when given with three days of AS. Comparable
results have been found in studies from Bie province in
Angola where the PCR-adjusted 28-day failure rate was
reduced from 25.3% for SP alone to 1.2% after addition
of AS and in Southern Benin where the PCR-corrected fail-
ure rate of AS+SP at 28 days was reduced from 44.1% to
5.3% when combining AS to SP [14,15]. In contrast, in
Boende the failure rate of SP alone was 36% and only
dropped to 25% when AS was added.
Table 2: Variations of fever, parasitaemia and haemoglobin over the time in the studies in Boende and Kabal
Boende Kabalo
Characteristics
N
SP
107
AQ
106
AS+SP
91
AS+AQ
90
p SP
60
AS+SP
62
AS+AQ
58
p
Proportion febrile d1 (%) 20/106
(18.7)
9/105
(8.5)
8/91
(8.8)
5/89
(5.6)
0.01 9/59
(15.3)
5/62
(8.1)
5/58
(8.6)
0.37
Proportion febrile d2 (%) 21/103
(20.4)
3/105
(2.8)
3/91
(3.3)
2/87
(2.2)
<0.001 13/58
(22.4)
1/62
(1.6)
1/58
(1.7)
<0.001
Proportion parasitaemic d2(%) 84/103
(81.5)
90/105
(85.7)
60/91
(65.9)
56/87
(64.4)
<0.001 35/58
(60.3)
8/62
(12.9)
9/58
(15.5)
<0.001
Proportion parasitaemic d7(%) 12/97
(11.4)
6/98
(6.1)
25/89
(28.1)
25/85
(29.4)
<0.001 5/51
(9.8)
7/60
(11.7)
1/54
(1.8)
0.12
Hb d0
median [range]
9.7
[6.0–12.7]
9.7
[5.0–11.7]
9.7
[6.7–12.7]
9.7
[6.7–12.7]
10.7
[6.7–12.7]
10.7
[6.7–14.0]
10.7
[6.0–14.0]
Anaemia* d0 (%) 100
(93.4)
102
(96.2)
83
(91.2)
83
(92.2)
0.51 31
(51.7)
39
(62.9)
36
(62.1)
0.38
Hb d28
median [range]
10.7
[6.7–12.7]
10.7
[6.7–12.7]
10.7
[7.0–12.7]
10.7
[7.3–12.7]
11.7
[10.7–12.7]
11.7
[9.7–12.7]
11.7
[9.7–14.0]
* Defined by haemoglobin below 11 g/dL
Table 3: PCR genotyping results after day 9 in the studies in Boende and Kabalo
Boende Kabalo
SP AQ AS+SP AS+AQ SP AS+SP AS+AQ
Recurrences,(N) 53 51 47 35 11 10 5
Recrudescence, N(%) 31(58.5) 16(31.4) 20(42.5) 11(31.4) 3(27.3) 0 0
Reinfection, N(%) 19(35.8) 33(64.7) 20(42.5) 18(51.4) 5(45.4) 8(80) 4(80)
No PCR result*, N(%) 3(5.7) 2(3.9) 7(14.9) 6(17.1) 3(27.3) 2(20) 1(20)
*missing, indeterminate or failure of DNA amplificationMalaria Journal 2009, 8:192 http://www.malariajournal.com/content/8/1/192
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It is not that surprising that in a large country, such as
DRC, considerable differences in anti-malarial efficacy
between provinces were observed. Site-specific patterns of
treatment-seeking behaviour or malaria transmission
intensity may explain geographical differences in the effi-
cacy of anti-malarial treatments [16-18]. The higher rein-
fection rate and higher proportion of anaemic children in
Boende suggest higher transmission intensity there.
A limitation of these studies is the disappointing external
quality control results, which suggest a failure of the inter-
nal quality control system in place. In the case of the
Boende study, it is important to note that for the majority
of discordant results the parasitaemia detected by one of
the laboratories was less than 100/μL. Also, these results
affected the classification of outcome in only three cases
in Boende and none in Kabalo. The delay of some months
before the EQC will have resulted in a deterioration in
slide quality, which may partially explain these poor
results. Having an adequate standard of microscopy even
in these circumstances is critical. The experience at these
two sites suggests that internal quality control measures in
place were not adequate to guarantee this standard. Exter-
nal quality control at regular intervals may be the answer
but is expensive, labour-intensive and the second reading
needs to be timely to avoid excessive deterioration of
slides, or slides need to be mounted. Sending a random
sample of slides seems an obvious approach but leads to
problems when agreement is not high. It is then recom-
mended that all the slides be sent, by which time several
months may have elapsed since the study has finished.
Conducting in vivo efficacy studies in remote regions, in
which there is political instability, is a major challenge.
Proxy markers for resistance, such as molecular markers
are invaluable tools to assess anti-malarial resistance in
such a context, being less resource demanding than an in
vivo  study. Unfortunately, there are no markers, which
reliably predict clinical resistance to drugs other than SP.
Data from neighbouring Congo-Brazzaville to the west
indicate high level SP and AQ resistance [19,20]. Efficacy
of AS+AQ in studies in Burundi and Tanzania to the East
in 2002 and 2004 respectively was high, although in the
Tanzanian study efficacy of amodiaquine alone was eval-
uated but not reported [21,22]. The observation of vary-
ing efficacy of the same anti-malarial in two different
regions in the same country shows the problem of imple-
menting a uniform national policy, especially in large
country like DRC. While these results cannot be general-
ized to the whole provinces (Katanga or Equatorial) and
even less to the whole country, they should alert the
national programme to foci of resistance to AS+AQ, which
became the national treatment policy in 2005. Efficacy of
ACTs including partner drugs to which there is pre-exist-
ing resistance such as SP or AQ, need to be monitored at
very regular intervals. According to the 2006 WHO Africa
Malaria Report, eight sentinel sites are now operational in
DRC [23].
Table 4: Failure rates at Day 28 after PCR adjustment in the studies in Boende and Kabalo
Boende Kabalo
Outcome
N
SP
76
AQ
66
AS+SP
61
AS+AQ
58
SP
48
AS+SP
49
AS+AQ
52
ETF, n (%) 2 (2.6) 0 0 0 8 (16.7) 0 0
LCF, n (%) 16 (21.0) 10 (15.1) 13 (21.3) 8 (13.8) 3 (6.3) 0 0
LPF, n (%) 1 (19.7) 7 (10.6) 7 (11.5) 3 (5.2) 0 0 0
Overall failure rate1
% [95% CI]
35.9
[27.0–46.7]
18.3
[11.6–28.1]
24.6
[16.6–35.5]
15.1
[8.6–25.7]
19.6
[11.4–32.7]
0
[0–5.8]2
0
[0–6.2]2
WHO 2001 outcome definitions used.
ETF: early treatment failure; LFU: lost to follow-up; LCF: late clinical failure; LFP: late parasitological failure; ACPRA: adequate clinical and 
parasitological response
1 Estimated by Kaplan-Meier Survival Analysis, reinfections censored on day endpoint classified. Patients with missing or unresolved PCR results 
censored on last day seen with negative malaria smear result.
2 One sided CI for a proportion calculated (Wilson method)
Table 5: Prevalence of mutations at codons 108, 51, 59 in dhfr, 
and of mutations at codons 437, 540 of dhps in the study in 
Boende, N = 102
N% 9 5 %  C I
Dhfr
- Sensitive 3 2.9 0.6–8.3
- Single-mutant 108 2 2.0 0.2–6.9
- Doublemutant 108, 51 31 30.4 21.7–40.3
- Double-mutant 108, 59 4 3.9 1.1–9.7
- Triple mutant 108, 51, 59 62 60.8 50.6–70.3
❍ Mixte 44 43.1 33.4–53.3
❍ Pure 18 17.6 10.8–26.4
Dhps
- Sensitive 30 29.4 20.8–39.2
- Single 68 66.7 56.6–75.7
- Double mutation 437, 540 4 3.9 1.1–9.7
❍ Mixte 1 1.0 0.0–5.3
❍ Pure 3 2.9 0.6–8.3Malaria Journal 2009, 8:192 http://www.malariajournal.com/content/8/1/192
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Since these studies were performed WHO pre-qualified
anti-malarials have become available, e.g. artemether-
lumefantrine and AS+AQ fixed-dose combination (FDC).
Dihydroartemisinin-piperaquine and the FDC of artesu-
nate-mefloquine are in the process of being registered.
Both artemether-lumefantrine and dihydroartemisinin-
piperaquine have been evaluated in a number of African
countries and appear highly efficacious [24,25]. The
NMCP of DRC may need to consider regional adjustments
to its policy guidelines, although such an approach is
challenging. DRC is participating in the World Bank
Booster programme worth $US30 million over four years,
which finances provision of long-lasting insecticidal nets
(LLINs), intermittent preventive treatment (IPT) for preg-
nant women and ACT as first-line treatment of malaria
http://web.worldbank.org. It is important that concomi-
tant monitoring of anti-malarial efficacy is supported in
order to inform policy makers [26].
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